Skip to main content

Table 2 Main reasons anticoagulant not used in males with CHA2DS2-VASc ≥2, and females with CHA2DS2-VASc ≥3

From: Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry

 

Netherlands (N = 66)

n (%)

World (N = 11,630)

n (%)

Alcohol abuse

0 (0.0)

48 (0.4)

Already taking AP for other medical condition

3 (4.5)

628 (5.4)

Patient refusal

1 (1.5)

911 (7.8)

Previous bleeding event

2 (3.0)

211 (1.8)

Taking medication contraindicated or cautioned for use with OAC

1 (1.5)

78 (0.7)

Other

12 (18.2)

1682 (14.5)

Unknown

19 (28.8)

4588 (39.4)

Physician’s choice

28 (42.4)

3484 (30.0)

 Bleeding risk

5 (7.6)

836 (7.2)

 Concern over patient compliance

0 (0.0)

412 (3.5)

 Guideline recommendation

0 (0.0)

237 (2.0)

 Fall risk

0 (0.0)

401 (3.4)

 Low risk of stroke

8 (12.1)

677 (5.8)

 Other

15 (22.7)

921 (7.9)

  1. AP Antiplatelet drug, OAC Oral anticoagulation